For example, DNMT3A R882 mutations were more common in AML; TET2, SRSF2 and SF3B1 mutations in MDS and JAK2; and CALR and MPL in MPN (Fig. 2c and Supplementary Fig. 2). This evidence concerns the gene TET2 and myeloproliferative disorder.